Opus Genetics (IRD) Other Operating Expenses (2010 - 2024)

Opus Genetics' (IRD) quarterly Other Operating Expenses came in at $28.0 million in Q4 2024, up 234.29% on a QoQ basis from $8.4 million in Q4 2020.

Opus Genetics (IRD) Other Operating Expenses (2010 - 2024) Analysis & Trends

Opus Genetics (IRD) has 6 years of Other Operating Expenses data on file, last reported at $28.0 million in Q4 2024.

On a quarterly basis, Other Operating Expenses changed N/A year-over-year to $28.0 million in Q4 2024; TTM through Sep 2025 was $28.0 million, a N/A change from a year earlier, with the FY2024 full-year figure at $28.0 million, changed N/A from the prior year.
Other Operating Expenses for Q4 2024 stood at $28.0 million, up from $8.4 million in the prior quarter.
Over the last five years, Other Operating Expenses for IRD reached as high as $28.0 million in Q4 2024 and fell as low as $2.1 million in Q1 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	67,072.09 Bn	67,072.09 Bn	-
2	Nanobiotix	1,894.61 Bn	1,894.55 Bn	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-
4	BeOne Medicines	471.64 Bn	466.85 Bn	1.35 Bn
5	Vertex Pharmaceuticals	121.72 Bn	114.47 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	68.28 Bn	59.52 Bn	3.31 Bn
7	Belite Bio	61.40 Bn	61.40 Bn	-
8	Argenx Se	56.94 Bn	56.94 Bn	1.18 Bn
9	Revolution Medicines	37.37 Bn	37.37 Bn	-
10	Opus Genetics	263.72 Mn	203.72 Mn	-

Download Data